Personalized Medicine for Non–Small-Cell Lung Cancer: Implications of Recent Advances in Tissue Acquisition for Molecular and Histologic Testing

摘要: In light of recent advances in individualized therapy for non–small-cell lung cancer (NSCLC), molecular and histologic profiling is essential guiding therapeutic decisions. Results these analyses may have implications both response (eg, testing EGFR [epidermal growth factor receptor] mutations) safety contraindications squamous histology) NSCLC. Most patients with NSCLC present unresectable advanced disease; therefore, greater emphasis being placed on minimally invasive tissue acquisition techniques, such as small biopsy cytology specimens. Due to the need increasing information increasingly smaller sample sizes, efforts must be focused optimizing development more sensitive assays. Recent techniques specimen preservation help address this challenge lead enhanced personalized treatment